Doshi highlights the danger of speeding new antibiotics to market without adequate testing.
1 However, it is dangerous to question the threat from antimicrobial resistance, and such questions must not detract from the urgent need for new antimicrobial agents.
The reduction in mortality from infections worldwide between 1990 and 2013 highlighted by the Global Burden of Disease study coincides with improved infection control and the introduction of the surviving sepsis campaign.
2 This campaign emphasises the importance of the early identification and treatment of sepsis.
3
As an intensivist I manage sepsis every day and apply the principles of the surviving sepsis campaign protocol. Although recent studies have questioned the relevance of some aspects of this protocol, 4 the early administration of appropriate antibiotics is life saving. The treatment of sepsis is extremely challenging and many patients still die from septic shock. There are many reasons for this, but an important factor is that many people are infected with organisms that are resistant to multiple antibiotics and early empirical treatment is completely ineffective.
The suggestion that antibiotic stewardship will limit sales of new antimicrobials is correct.
1 However, irresponsible use of new antimicrobials will decimate sales by promoting the emergence of resistant organisms. The drug industry must take a long term view to ensure its own survival. After all, if we lose the war against micro-organisms there won't be a market for any of its products.
